Drug Patents Expiring in 2037

1. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Feb, 2037

(14 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

2. Drug name - AKYNZEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624911 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant Jun, 2037

(14 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL POWDER;INTRAVENOUS Prescription
EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - AMZEEQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398641 JOURNEY Compositions and methods for treating rosacea and acne Sep, 2037

(14 years from now)

US10849847 JOURNEY Compositions and methods for treating rosacea and acne Sep, 2037

(14 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 4% BASE AEROSOL, FOAM;TOPICAL Prescription

4. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034

(Pediatric)

TEVA PHARM Compliance monitoring module for a breath-actuated inhaler Feb, 2037

(14 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

5. Drug name - AUVI-Q

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688244 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children Dec, 2037

(15 years from now)

US10842938 KALEO INC Medicament delivery device and methods for delivering drugs to infants and children Dec, 2037

(15 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Method of treating an allergic reaction using an auto-injector

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.15MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.3MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription

6. Drug name - AZSTARYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same Dec, 2037

(15 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same Dec, 2037

(15 years from now)

US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same Dec, 2037

(15 years from now)

US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same Dec, 2037

(15 years from now)

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5.2MG BASE;EQ 26.1MG BASE CAPSULE;ORAL Prescription
EQ 7.8MG BASE;EQ 39.2MG BASE CAPSULE;ORAL Prescription
EQ 10.4MG BASE;EQ 52.3MG BASE CAPSULE;ORAL Prescription

7. Drug name - BRUKINSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927117 BEIGENE Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Aug, 2037

(14 years from now)

Drugs and Companies using ZANUBRUTINIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
80MG CAPSULE;ORAL Prescription

8. Drug name - CABOMETYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate Apr, 2037

(14 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

9. Drug name - CALCIUM GLUCONATE IN SODIUM CHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10342813 HQ SPCLT PHARMA Calcium gluconate solutions in flexible containers Jul, 2037

(14 years from now)

US10130646 HQ SPCLT PHARMA Calcium gluconate solutions in flexible containers Jul, 2037

(14 years from now)

Drugs and Companies using CALCIUM GLUCONATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/50ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription
1GM/100ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription
2GM/100ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription

10. Drug name - CEQUA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof Feb, 2037

(14 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: NA

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.09% SOLUTION;OPHTHALMIC Prescription

11. Drug name - DEFINITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents Mar, 2037

(14 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents Mar, 2037

(14 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents May, 2037

(14 years from now)

Drugs and Companies using PERFLUTREN ingredient

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6.52MG/ML INJECTABLE;INTRAVENOUS Prescription

12. Drug name - DRIZALMA SPRINKLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413525 SUN PHARM Duloxetine sprinkles Apr, 2037

(14 years from now)

US11202772 SUN PHARM Duloxetine sprinkles Apr, 2037

(14 years from now)

US9839626 SUN PHARM Duloxetine sprinkles Apr, 2037

(14 years from now)

US10959982 SUN PHARM Duloxetine sprinkles Apr, 2037

(14 years from now)

Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED REL PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, DELAYED REL PELLETS;ORAL Prescription
EQ 30MG BASE CAPSULE, DELAYED REL PELLETS;ORAL Prescription
EQ 40MG BASE CAPSULE, DELAYED REL PELLETS;ORAL Prescription
EQ 60MG BASE CAPSULE, DELAYED REL PELLETS;ORAL Prescription

13. Drug name - ESBRIET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188637 GENENTECH INC Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same Mar, 2037

(14 years from now)

More Information on Dosage
Strength Dosage Availability
267MG TABLET;ORAL Prescription
534MG TABLET;ORAL Discontinued
801MG TABLET;ORAL Prescription

14. Drug name - EVEKEO ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441554 ARBOR PHARMS LLC Oral amphetamine composition Mar, 2037

(14 years from now)

US11160772 ARBOR PHARMS LLC Oral amphetamine composition Mar, 2037

(14 years from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
5MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
10MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
15MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
20MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription

15. Drug name - FINTEPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603290 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same Aug, 2037

(14 years from now)

US11040018 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same Aug, 2037

(14 years from now)

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Treatment: Use in combination with cannabidiol for the treatment of seizures associated with dravet syndrome

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.2MG BASE/ML SOLUTION;ORAL Prescription

16. Drug name - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10293047 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions Nov, 2037

(15 years from now)

US10842872 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions Nov, 2037

(15 years from now)

US10632197 BAUSCH LOMB IRELAND Fluorescein and benoxinate compositions Nov, 2037

(15 years from now)

Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient

Treatment: Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic; Procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic.

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.4%;0.3% SOLUTION/DROPS;OPHTHALMIC Prescription

17. Drug name - GALAFOLD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076514 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene Mar, 2037

(14 years from now)

US11234972 AMICUS THERAP US Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene Mar, 2037

(14 years from now)

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 123MG BASE CAPSULE;ORAL Prescription

18. Drug name - GIAPREZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219662 LA JOLLA PHARMA Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II Jan, 2037

(14 years from now)

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

Treatment: Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML) SOLUTION;INTRAVENOUS Discontinued

19. Drug name - GLOPERBA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226423 ROMEG Colchicine drug-to-drug interactions Dec, 2037

(15 years from now)

Drugs and Companies using COLCHICINE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.6MG/5ML SOLUTION;ORAL Prescription

20. Drug name - GOPRELTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857095 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10016407 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US9867815 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10413505 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10420760 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10149843 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10933060 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10973811 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10987347 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10894012 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10231961 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US11040032 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; method of administering a local anesthetic to the mucous membranes in patients with renal impairment; method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method of administering a local anesthetic to the mucous membranes; method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment

Dosage: SOLUTION;NASAL

More Information on Dosage
Strength Dosage Availability
4% SOLUTION;NASAL Prescription

21. Drug name - HEMADY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537585 DEXCEL PHARMA Compositions comprising dexamethasone Dec, 2037

(15 years from now)

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription

22. Drug name - INGREZZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Treatment: Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; treatment of tardive dyskinesia; Treatment of tardive dyskinesia; method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer; Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription
EQ 60MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

23. Drug name - KATERZIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959991 AZURITY Amlodipine formulations Oct, 2037

(15 years from now)

US10952998 AZURITY Amlodipine formulations Oct, 2037

(15 years from now)

US10894039 AZURITY Amlodipine formulations Oct, 2037

(15 years from now)

US10695329 AZURITY Amlodipine formulations Oct, 2037

(15 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Treatment: Angina pectoris; angina; Treatment of hypertension; method of treating hypertension

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/ML SUSPENSION;ORAL Prescription

24. Drug name - KORLYM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10151763 CORCEPT THERAP Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome Jan, 2037

(14 years from now)

US10195214 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors Jun, 2037

(14 years from now)

US10842800 CORCEPT THERAP Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors Jun, 2037

(14 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

25. Drug name - LEXETTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857159

(Pediatric)

MAYNE PHARMA Halobetasol foam composition and method of use thereof May, 2037

(14 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.05% AEROSOL, FOAM;TOPICAL Prescription

26. Drug name - LONSURF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment Feb, 2037

(14 years from now)

US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment Feb, 2037

(14 years from now)

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Treatment: Method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 6.14MG BASE;15MG TABLET;ORAL Prescription
EQ 8.19MG BASE;20MG TABLET;ORAL Prescription

27. Drug name - LUPKYNIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286036 AURINIA Protocol for treatment of lupus nephritis Dec, 2037

(15 years from now)

Drugs and Companies using VOCLOSPORIN ingredient

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
7.9MG CAPSULE;ORAL Prescription

28. Drug name - MYFEMBREE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids Sep, 2037

(15 years from now)

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG;0.5MG;40MG TABLET;ORAL Prescription

29. Drug name - NUPLAZID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10953000 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators Mar, 2037

(14 years from now)

US10517860 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators Mar, 2037

(14 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 17MG BASE TABLET;ORAL Discontinued

30. Drug name - NUZYRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof Aug, 2037

(14 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) Oct, 2037

(15 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) Oct, 2037

(15 years from now)

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

Treatment: Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription

31. Drug name - ORGOVYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786501 MYOVANT SCIENCES Treatment of prostate cancer Sep, 2037

(15 years from now)

US10449191 MYOVANT SCIENCES Treatment of prostate cancer Sep, 2037

(15 years from now)

Drugs and Companies using RELUGOLIX ingredient

Treatment: Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
120MG TABLET;ORAL Prescription

32. Drug name - OTIPRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040004 ALK ABELLO Otic gel formulations for treating otitis externa Nov, 2037

(15 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Treatment: The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage
Strength Dosage Availability
6% (60MG/ML) INJECTABLE, SUSPENSION;OTIC Prescription

33. Drug name - OXBRYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde Oct, 2037

(15 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
500MG TABLET;ORAL Prescription

34. Drug name - PIZENSY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10806743 BRAINTREE LABS Method of administering lactitol to reduce plasma concentration of lactitol May, 2037

(14 years from now)

Drugs and Companies using LACTITOL ingredient

Treatment: Method of treating chronic idiopathic constipation in adult patients.

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
10GM FOR SOLUTION;ORAL Discontinued

35. Drug name - PYLARIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10947197 PROGENICS PHARMS INC Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL
Jun, 2037

(14 years from now)

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50ML (1-80mCi/ML) SOLUTION;INTRAVENOUS Prescription

36. Drug name - RETEVMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112942 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(15 years from now)

CN110382494A LOXO ONCOLOGY INC Substituted Pyrazole And [1-A] Pyridine Compound As The Ret Kinase Inhibitor
Oct, 2037

(15 years from now)

CN110382494B LOXO ONCOLOGY INC Substituted Pyrazolo [1, 5-A] Pyridine Compound As Ret Kinase Inhibitor
Oct, 2037

(15 years from now)

EP3523301A1 LOXO ONCOLOGY INC Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
Oct, 2037

(15 years from now)

EP3523301B1 LOXO ONCOLOGY INC Substituted Pyrazolo[1,5-A]Pyridine Compounds As Ret Kinase Inhibitors
Oct, 2037

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10172851 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Oct, 2037

(15 years from now)

US10137124 LOXO ONCOLOGY INC Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Oct, 2037

(15 years from now)

Drugs and Companies using SELPERCATINIB ingredient

Treatment: Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Prescription
80MG CAPSULE;ORAL Prescription

37. Drug name - REYVOW

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(15 years from now)

EP3551617B1 ELI LILLY AND CO Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists
Dec, 2037

(15 years from now)

EP3551617A1 ELI LILLY AND CO Compositions And Methods Related To Pyridinoylpiperidine 5-Ht1F Agonists
Dec, 2037

(15 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Discontinued

38. Drug name - ROZLYTREK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10738037 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2037

(14 years from now)

CN109153669A GENENTECH INC N - [5 - (3, 5-Difluoro-Benzyl) -1H - Indazol - -3 - Yl]--4-(4-Methyl-Piperazin - -1 - Yl)--2-(Tetrahydropyran - -4 - Ylamino) - Form
May, 2037

(14 years from now)

CN109153669B GENENTECH INC New Crystal Form Of Benzamide Compound
May, 2037

(14 years from now)

EP3464276A1 GENENTECH INC New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide
May, 2037

(14 years from now)

EP3464276B1 GENENTECH INC New Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydropyran-4-Ylamino)-Benzamide
May, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091469 GENENTECH INC Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May, 2037

(14 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: Treatment of ros1-positive non-small cell lung cancer; treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription
200MG CAPSULE;ORAL Prescription

39. Drug name - SAXENDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO Liraglutide in cardiovascular conditions Jan, 2037

(14 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions Jul, 2037

(14 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

40. Drug name - SUNOSI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10195151 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate Sep, 2037

(14 years from now)

US10512609 JAZZ Formulations of (R)-2-amino-3-phenylpropyl carbamate Sep, 2037

(14 years from now)

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

41. Drug name - SUTAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143656 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same Aug, 2037

(14 years from now)

US11033498 BRAINTREE LABS Solid oral sulfate salt formulations for cleaning a colon and methods of using same Aug, 2037

(14 years from now)

Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient

Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.225GM;0.188GM;1.479GM TABLET;ORAL Prescription

42. Drug name - TIROSINT-SOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537538 INSTITUT BIOCHIMIQUE High-stability packaged solutions of T4 thyroid hormone Feb, 2037

(14 years from now)

US11096913 INSTITUT BIOCHIMIQUE High-stability packaged solutions of T4 thyroid hormone Feb, 2037

(14 years from now)

More Information on Dosage
Strength Dosage Availability
13MCG/ML SOLUTION;ORAL Prescription
25MCG/ML SOLUTION;ORAL Prescription
37.5MCG/ML SOLUTION;ORAL Prescription
44MCG/ML SOLUTION;ORAL Prescription
50MCG/ML SOLUTION;ORAL Prescription
62.5MCG/ML SOLUTION;ORAL Prescription
75MCG/ML SOLUTION;ORAL Prescription
88MCG/ML SOLUTION;ORAL Prescription
100MCG/ML SOLUTION;ORAL Prescription
112MCG/ML SOLUTION;ORAL Prescription
125MCG/ML SOLUTION;ORAL Prescription
137MCG/ML SOLUTION;ORAL Prescription
150MCG/ML SOLUTION;ORAL Prescription
175MCG/ML SOLUTION;ORAL Prescription
200MCG/ML SOLUTION;ORAL Prescription

43. Drug name - TRIKAFTA (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10793547 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(15 years from now)

EP3551622B1 VERTEX PHARMS INC Modulator Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process For Making The Modulator
Dec, 2037

(15 years from now)

EP3551622A1 VERTEX PHARMS INC Modulator Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process For Making The Modulator
Dec, 2037

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11179367 VERTEX PHARMS INC Pharmaceutical compositions for treating cystic fibrosis Dec, 2037

(15 years from now)

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a composition according to at least one of claims 1-9 of us11179367

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG,37.5MG,25MG; 75MG TABLET;ORAL Prescription
100MG,75MG,50MG; 150MG TABLET;ORAL Prescription

44. Drug name - VICTOZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions Jan, 2037

(14 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions Jul, 2037

(14 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administering liraglutide

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

45. Drug name - VITRAKVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10668072 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr, 2037

(14 years from now)

US10045991 BAYER HEALTHCARE Methods of treating pediatric cancers Apr, 2037

(14 years from now)

US10137127 BAYER HEALTHCARE Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide Apr, 2037

(14 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/ML SOLUTION;ORAL Prescription

46. Drug name - VOSEVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912814 GILEAD SCIENCES INC Combination formulation of three antiviral compounds Jun, 2037

(14 years from now)

More Information on Dosage
Strength Dosage Availability
400MG;100MG;100MG TABLET;ORAL Prescription

47. Drug name - XERAVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10961190 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(15 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription
EQ 100MG BASE/VIAL POWDER;INTRAVENOUS Prescription

48. Drug name - XOFLUZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10759814 GENENTECH INC Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Aug, 2037

(14 years from now)

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription

49. Drug name - ZULRESSO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940156 SAGE THERAP Neuroactive steroids, compositions, and uses thereof Mar, 2037

(14 years from now)

Drugs and Companies using BREXANOLONE ingredient

Treatment: Method of treating postpartum depression

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/20ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.